Abstract
Non-obese diabetic (NOD) mice are well-established models of independently developing spontaneous autoimmune diseases, Sjögren’s syndrome (SS) and type 1 diabetes (T1D). The key determining factor for T1D is the strong association with particular MHCII molecule and recognition by diabetogenic T cell receptor (TCR) of an insulin peptide presented in the context of I-Ag7 molecule. For SS the association with MHCII polymorphism is weaker and TCR diversity involved in the onset of the autoimmune phase of SS remains poorly understood. To compare the impact of TCR diversity reduction on the development of both diseases we generated two lines of TCR transgenic NOD mice. One line expresses transgenic TCRβ chain originated from a pathogenically irrelevant TCR, and the second line additionally expresses transgenic TCRαmini locus. Analysis of TCR sequences on NOD background reveals lower TCR diversity on Treg cells not only in the thymus, but also in the periphery. This reduction in diversity does not affect conventional CD4+ T cells, as compared to the TCRmini repertoire on B6 background. Interestingly, neither transgenic TCRβ nor TCRmini mice develop diabetes, which we show is due to lack of insulin B:9–23 specific T cells in the periphery. Conversely SS develops in both lines, with full glandular infiltration, production of autoantibodies and hyposalivation. It shows that SS development is not as sensitive to limited availability of TCR specificities as T1D, which suggests wider range of possible TCR/peptide/MHC interactions driving autoimmunity in SS.
Introduction
NOD mice serve as well-established models of independently developing autoimmune diseases, Type 1 Diabetes (T1D) and Sjögren’s syndrome (SS) [1], [2]. T1D is characterized by autoimmune attacks against the pancreatic beta-cells with T cells playing an essential role in the initiation and progression of the disease, leading to hyperglycemia and vascular complications [3], [4]. SS is an autoimmune disease with local and systemic manifestations, characterized by mononuclear infiltrates into salivary and lacrimal glands leading to clinical symptoms of dry mouth and dry eyes [5], [6]. Glandular infiltrates consist mostly of CD4+ T cells with lesser amounts of CD8+ T cells and B cells. Although factors like viral or bacterial infections, aberrant glandular development or cytokine production are important in the initial phase of the pathogenesis of SS, CD4+ T cells are important players in the onset of autoimmunity and disease progression.
Autoimmunity in NOD mice is attributed to several different events occurring in the thymus and in the periphery. Studies in these mice showed a defect in negative selection [7], perturbed αβ/γδ lineage decision leading to a shift in selection niches [8], reduced relative diversity of thymic Treg cells [9], peripheral hyper-responsiveness of effector CD4+ T cells [10], multiple binding registers of insulin B:9–23 peptide resulting in poor negative selection in the thymus [11], [12], or peripheral post-translational modification of self-peptides/neo-antigens [13]. Despite genetic predispositions, the key component in the development of autoimmune diseases is the recognition of a particular antigen in the context of MHC Class II molecule by CD4+ T cells. The development of diabetes in NOD mice is associated with the key I-Ag7 molecule (HLA-DQ8 in humans) in the absence of a functional I-E molecule [14], [15]. Co-expression of other MHC molecules with I-Ag7 can prevent development of diabetes in a dominant fashion [14], [15]. Replacement of I-Ag7 with other MHC molecules, like I-Ab, I-Ap or I-Aq, does not promote the development of diabetes yet mice continue to develop autoimmune exocrinopathy and the severity of the SS and the profile of antibodies’ specificities vary between congenic mice [16]. In large-scale association study of SS in humans, HLA was found to have the strongest linkage to the disease [17].
The strict dependence of T1D on the particular MHC allele correlates with its primary antigen requirement where insulin B:9–23 peptide has been identified as the epitope necessary for onset of the disease in NOD mice [18]. In SS, no key epitope(s) are identified, although several proteins have been implicated as a source of antigens: Ro/SSA 52 kDa, αFodrin, Muscarinic Acetylcholine 3 Receptor (M3R), α-amylase, islet cell autoantigen-69, kallikrein-13 [19]–[24]. Recently it has been shown that the transfer of T cells from M3R-immunized M3R−/− mice into Rag−/− mice leads to development of sialadenitis, showing pathogenic potential of M3R specific T cells [25].
Despite the strict requirement of the presence of the insulin B:9–23/I-Ag7 combination, the development of T1D in NOD mice proceeds even when total TCR diversity and precursor frequency of diabetogenic TCRs is limited. The reduction of TCR diversity by use of TCRβ transgenic mice [26], or great reduction of precursor frequency relying on allelic exclusion escapees on NOD background does not prevent development of T1D [27], although not all endogenous TCRβ chains are permissive for the development of insulin B:9–23 specific TCRs [28]. In SS it is not clear as to what role diversity of interactions between TCRs and different peptide/MHCII complexes play in the onset and development of the disease. Previous studies in patients with SS found that TCR repertoire of infiltrating T cells is to some extent restricted with different dominant clonotypes of Vβ families [29]–[33]. Despite the lack of dominant Vα/Vβ families or dominant specificity in different patients these studies show clonal expansion of infiltrating T cells, which suggests that the number of epitopes participating in the autoimmunity of the disease is limited [34], [35]. However, the weaker dependence of SS on MHC polymorphism suggests broad diversity of possible TCR/peptide/MHCII interactions participating in the pathogenesis of the disease. As the diversity of antigenic specificities and TCR repertoire on T cells involved in SS development is not well understood, we wanted to compare sensitivity of development of SS versus T1D to the diminishing diversities of TCRs in the presence of the same I-Ag7 molecule in NOD mice. To reduce the diversity of TCRs in NOD mice we generated two types of transgenic strains, in which all T cells express either one transgenic TCRβ chain or additionally co-express TCRα chains from TCRαmini locus [36]. Interestingly, these mice do not develop T1D but still develop SS with glandular infiltrations, autoantibody presence and hyposalivation. We investigated the reasons for the lack of T1D development and the role of reduced diversity on generated repertoires of TCRs on conventional and regulatory T cells in the thymus and periphery of NOD mice.
Materials and Methods
Ethics statement
All mice used in this study were housed in the animal care facility at the Georgia Regents University (GRU). All work involving animals was conducted under protocols approved by the Animal Care and Use Committee at the GRU (#2008−0231). All efforts were made to minimize suffering. Mice were euthanized by CO2 followed by cervical dislocation.
Mice
Production of TCRβTg and TCRαmini constructs and generation of transgenic mice on C57BL/6 (B6) background was described previously (Pacholczyk 2006). A similar strategy was used to microinject one or both DNA constructs into zygotes of NOD mice (Transgenic Mice Core Facility, GRU). To eliminate expression of endogenous TCRα chains, NOD.TCRβTg.TCRαmini transgenic mice were crossed with NOD.TCRα−/− (NOD.129P2(C)-Tcratm1Mjo/DoiJ) mice purchased from The Jackson Laboratory (Bar Harbor, ME). To facilitate identification of Treg cells both transgenic lines then were crossed with NOD.FoxP3GFP/cre mice (NOD/ShiLt-Tg(Foxp3-EGFP/cre)1Jbs/J) purchased from The Jackson Laboratory. The B6.Aec1Aec2 (B6.DC) mice were kindly provided by Dr. Ammon Peck [37].
Histology
Organs were removed from each mouse at the time of euthanasia, placed in 10% phosphate-buffered formalin for at least 24 h and then embedded in paraffin. Sections were taken at 5 µm of thickness 200 µm apart. The tissue sections were stained with hematoxylin and eosin (H&E) at the Histology Core Laboratory, GRU. One infiltrate was defined as a cluster of at least 50 nucleated cells, scoring described in figures.
Measurement of saliva flow
Mice were given an i.p. injection of 100 µl of pilocarpine (0.05 mg/ml in PBS) per 20 g of body weight. Saliva was collected for 10 min., starting 1 min. after injection of pilocarpine. The volume of saliva was measured and normalized to the mouse body weight.
Detection of auto-antibodies
Auto-antibodies and total IgG1 were measured using mouse serum with the following ELISA kits: αFodrin (American Research Products), ANA, ssDNA, dsDNA (Immuno-Biological Laboratories) and IgG1 (Immunology Consultants Laboratory). Assays were performed according to manufacturer’s protocols with serum dilution 1∶100 and 1∶50,000 for IgG1. OD450 values of negative samples were subtracted from the OD450 of experimental samples.
Cell preparation, flow cytometry and cell sorting
Cells were isolated from peripheral lymph nodes (axillary, brachial and inguinal) and thymii by mechanical disruption through nylon mesh. Salivary mandibular and extraorbital lacrimal glands were first cut and digested using collagenase (1 ug/ml) for 30 min in 37°C. Cells were washed and counted (Countess, Invitrogen) and used for staining with monoclonal antibodies: CD4 (clone RM4-5), CD8α (53-6.7), B220 (RA3-6B2), TCRVα2 (B20.1), TCRVβ14 (14-2), TCRβ (H57-597), CD25 (PC61), CD45RB (16A), CD62L (MEL-14), all from BD Biosciences. Stained cells were either analyzed using FACS Canto (BD Biosciences) or sorted on MoFlo Sorter (Cytomation). Dead cells were excluded using forward vs side scatter dot plots and doublets discrimination was accomplished using forward scatter height vs width dot plots. Purities of all sorted populations were above 98%.
Immunization and generation of T cell hybridomas
Mice were immunized at the base of the tail with 50 µg of insulin B:9–23 peptide emulsified in Complete Freund’s Adjuvant (Thermo Scientific). One week later lymphocytes were isolated from draining lymph nodes and cultured in vitro for 3–4 days with insulin B:9–23 peptide (50 µg/ml), followed by 3–4 days of expansion with murine recombinant IL-2 (20 U/ml, Peprotech). For generation of allo-specific T cell hybridomas, CD4+ T cells sorted from un-immunized experimental mice were stimulated in vitro by co-culture with splenocytes from B6.TCRα−/− mice, followed by expansion with IL-2. Activated T cells were fused to BW5147 TCRα-β- NFAT-EGFP cells as previously described [38]. BW NFAT-EGFP fusion partner expresses GFP protein under the minimal human IL-2 promoter, which contains NFAT-binding sites [39]. T cell hybridomas were selected using HAT (Cellgro) selection media by limiting dilution method. For stimulation, cloned T cell hybridomas (105 cells) were co-cultured overnight with 5×105 splenocytes (from NOD.TCRα−/− or B6.TCRα−/− mice) with or without insulin B:9–23 peptide (50 µg/ml) or anti-CD3 antibody (1 µg/ml). Specific activation of the hybridomas was measured by detection of GFP-positive cells or by detection of IL-2 in culture supernatant using CBA Mouse IL-2 Flex Set (BD Biosciences).
MTT assay
The proliferation of the cells was measured using 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma) assay. On the third day of in vitro stimulation 10 µl of MTT (5 mg/ml) was added to each well and incubated for 4 h. After discarding supernatant, the remaining formazan precipitates were dissolved in 150 ul of 70% isopropanol solution (70% isopropanol, 30% water, 0.02N hydrochloric acid) overnight. Absorbance was measured at 570 nm using Microplate Reader (Biotek Synergy HT).
Sequencing
Single cell sorting and sequencing was done as previously described [36]. High-throughput sequencing was done using Ion Torrent platform (Life Technologies) by Genomic Core Facility at GRU. Libraries of the TCRs were prepared according to protocol. Shortly, CDR3α regions were amplified using primers specific for Vα2 and Cα segments with integrated adapters and barcodes, provided by manufacturer. Before sequencing, consistency of samples was checked by 2D-F-SSCP analysis of PCR products from three aliquots of cDNA per each sample [36]. Only samples with three similar/identical profiles were considered without PCR bias and were used for further purification using Agencourt AMPure XP reagent (Beckman Coulter) and used for sequencing. FASTQ files with sequences were processed and analyzed using custom-written program in Pearl (ActivePearl, ActiveState Software Inc.). Sequences with quality score of CDR3α region above 27 were used for analysis. The length of CDR3α region was defined by counting from the third amino acid after the invariant C residue in all Vα regions (Y-L/F-C-A-X-first) to the amino acid immediately preceding common Jα motif (last-F-G-X-F-G-T).
Statistical analysis
The similarity, diversity and richness estimators were calculated using programs designed to measure biodiversity: EstimateS8.2 (Colwell, R. EstimateS: Biodiversity Estimation Software. Program and User’s Guide at http://viceroy.eeb.uconn.edu/estimates) and SPADE (Chao, A. and Shen, T.-J. (2010) Program SPADE (Species Prediction And Diversity Estimation). Program and User’s Guide published at http://chao.stat.nthu.edu.tw).
Results
Development of T cells in NODβTg and NODmini mice
We generated TCRβ transgenic mice, in which all T cells use the same TCRβTg chain (Vβ14Dβ2Jβ2.6) and one of the endogenous TCRα chains. The TCRβ transgenic chain originated from I-Ab restricted TCR specific to Ep63 K peptide an analog of Eα 52–68 peptide in which the residue at position 63(I) was substituted with lysine [40]. To further reduce diversity of TCRs we used TCRαmini transgenic construct, used previously to create TCRmini mouse on B6 background (B6mini) [36]. The TCRαmini transgene allows a single Vα2.9 segment to rearrange to one of the two Jα (Jα26 and Jα2) segments. The generated transgenic mice were further crossed with TCRα−/− mice to ensure that all developing T cells use transgenic TCRαmini locus. To track CD4+ Foxp3+ regulatory T (Treg) cells we crossed transgenic mice with NOD.Foxp3.EGFP/cre mice as described in methods. Final characteristics of mice used in this paper were NODmini (NOD.TCRαmini.TCRβTg.TCRα−/−.Foxp3EGFP/cre), NODβTg (TCRβTg.TCRα+/−.Foxp3EGFP/cre) and NOD (NOD.Foxp3EGFP/cre).
In NODmini and NODβTg transgenic mice thymic development of T cells proceeds normally, and selection of single positive (SP) thymocytes is very efficient with bias toward CD4+ T cells in the thymus and in the periphery, similarly to a previously reported bias on B6 background (Fig. 1A, 1B) [36]. TCRβ transgenic mice are characterized by allelic exclusion, resulting in all T cells to express only one transgenic TCRβ chain. It has been proposed that allelic exclusion in NOD mice is less efficient [27]. In our mice all SP thymocytes and peripheral T cells have exclusive expression of transgenic TCRβTg chain (TCRVβ14) in both types of transgenic mice and exclusive expression of TCRαmini transgene (TCRVα2) in NODmini mice (Fig. 1A, 1B). Also we did not observe emergence of the cells bearing TCRs with Vβ segments other than Vβ14 even in older mice. Furthermore, we observed lower percentages of Treg cells in thymii and periphery of transgenic mice as compared to NOD mice and the percentages correlated with diversities of TCRs in analyzed mice (Fig. 1C, 1E). Nevertheless, the total numbers of peripheral Treg cells were similar in all of analyzed mice and reduced percentages of Treg cells were due to more efficient selection of CD4+ T cells, rather than diversity of TCRs, as we observed this correlation on B6 background and in other types of mice that differ by efficiency of CD4+ T cells selection (Fig. 1C, 1E) [36], [41]. Finally, to check whether this particular TCRVβ14 transgenic chain can impose an unusual restriction on the TCRα repertoire, we evaluated the frequency of individual Vα families. We found no bias in TCR repertoire as the frequency of Vα families usage by CD4+Vβ14+ T cells was similar between NOD and NODBTg mice (Fig. 1D).
Lack of T cells specific to insulin B:9–23 in NOD transgenic mice
To test development of diabetes we measured blood glucose levels in experimental mice. Surprisingly, neither NODβTg nor NODmini transgenic mice develop diabetes (Fig. 2A). Evaluation of H&E stained pancreatic sections showed lack of lymphocytic infiltrates in 25 week old transgenic mice, with only insignificant infiltrates found in a few sections of NODβTg mice (Fig. 2B). As a control we used non-transgenic littermates of NODβTg, NOD.TCRα+/− mice. These mice developed diabetes and by 30 weeks of age more than 75% of females had high levels of blood glucose (Fig. 2A). One of the possibilities was that the lack of development of diabetes in transgenic mice is due to perturbed proportions of regulatory to effector T cell ratios, which could result in more efficient suppression of potentially diabetogenic T cells. We took advantage of cyclophosphamide treatment, which selectively affects numbers and function of Treg cells and accelerates development of diabetes in NOD mice [42], [43]. This treatment however did not cause insulitis nor diabetes in transgenic mice indicating inability of effector T cells to initiate autoimmunity (unpublished data).
The onset of spontaneous diabetes in NOD mice is dependent upon presence of effector T cells specific to insulin B:9–23 antigen and lack of such specificity results in lack of early infiltrates into pancreatic islets [18]. As our mice did not develop islet-infiltrates, we tested their ability to respond to stimulation by insulin B:9–23 peptide (Fig. 3). CD4+ T cells isolated from NODmini, NODβTg and NOD mice responded to stimulation by allogeneic splenocytes, however only CD4+ T cells from immunized NOD mice were able to respond to B:9–23 peptide in the presence of syngeneic splenocytes (Fig. 3). As of note, B:9–23 peptide does not bind to I-Ab molecule and in the presence of B6 splenocytes does not lead to CD4 T cell response [44]. We were also unable to generate B:9–23 specific T cell hybridomas from immunized NODmini and NODβTg mice, however we had no problem generating allo-specific T cell hybridomas from transgenic mice. These results showed that changes introduced by transgenic chains to the TCR repertoire in NOD mice resulted in lack of peripheral specificity to the key antigen required for onset of T1D.
Development of SS in NODβTg and NODmini mice
The lack of T1D in transgenic mice prompted us to test whether reduced TCR diversity will affect development of Sjögren’s syndrome – secondary autoimmune disease in NOD mice. It is characterized by lymphocytic infiltrates into salivary and lacrimal glands, production of auto-antibodies and the loss of saliva and tear production by 20 weeks of age [5], [45]. Histological evaluation of tissue sections of submandibular salivary and extraorbital lacrimal glands showed focal lymphocytic infiltrates, in both transgenic NODmini and NODβTg and parental NOD mice (Fig. 4). Similarly to the NOD mice, males of both transgenic mice had milder infiltration of salivary glands than females, while the infiltration of lacrimal glands was more prominent in male NODβTg and NODmini mice. This infiltration is organ specific, as we did not detect infiltrates in lungs, kidney, liver, as well as sublingual and parotid salivary glands and harderian lacrimal glands of 20 week old transgenic mice, similarly to NOD mice (Fig. 4B). Of note, in some of 30 week old NODmini females, but not NODβTg mice, we noticed development of lymphoproliferation, manifested by enlarged lymph nodes and spleen and infiltration into multiple organs (unpublished data). FACS analysis of lymphocytic infiltrates in affected exocrine glands showed that all of the infiltrating CD4+ T cells expressed transgenic Vβ14 chain in NODβTg mice and Vβ14/Vα2 transgenic chains in NODmini mice (Fig. 4C). This also showed the aforementioned stability of expression of transgenic TCRs in experimental mice.
Development of SS in humans is often correlated with presence of anti-nuclear antibodies (ANA), anti-Ro/SSA, anti-La/SSB, anti-dsDNA, anti-αFodrin and anti-M3R [5], [22], [46]. In the NOD mouse model of SS, anti-SSA and anti-SSB auto-antibodies are rarely present and they are found at the very low levels [47]. To determine the presence of auto-antibodies in experimental mice, we used ELISA-based assay. For negative control, we used sera from NOD.TCRα−/− mice, that do not have T cells. As shown in Fig. 5, transgenic and parental NOD mice from 14–17 week old group had elevated levels of antibodies against αFodrin, ssDNA, dsDNA and ANA. Additionally, we determined the staining pattern of ANA auto-antibodies using immunofluorescent staining of HEp-2 cells (Fig. 5B). The majority (>90%) of NODmini and NODβTg mice tested had a speckled nuclear staining pattern, characteristic for SS development and found in parental NOD mice.
The onset of salivary gland dysfunction and presence of autoantibodies relies on B cells involvement and is dependent on IL-4 mediated IgM to IgG1 class switching [48]–[50]. Analysis of IgG1 concentration in sera of experimental mice revealed increased levels in older mice with the highest level in NODmini mice (Fig. 5C). This increase in IgG1 titer correlates with detection of auto-antibodies. Finally, to evaluate glandular dysfunction, we quantified secretion of saliva in 20 wks old mice. Both NODβTg and NODmini mice had reduced saliva flow as compared to healthy B6 mice and at the level of the reference parental NOD mice (Fig. 5D). Taken together, glandular infiltration, autoantibody production, and defective salivary secretion is diagnostic of Sjögren’s syndrome in transgenic NODβTg and NODmini mice, similarly to the parental strain of NOD mice. Interestingly, the timing of infiltrates and levels of autoantibodies and total IgG1 production vary between analyzed mice, which differ only by TCR repertoire diversity.
Diversity of TCR repertoire on CD4+ T cells in NODmini mice
Lack of certain specificities in NODmini TCR repertoire and the previously reported lower TCR diversity of thymic Treg cells on NOD background prompted us to take a closer look at the similarity and diversity of TCRαmini repertoires. To determine the influence of TCR diversity reduction on the selection efficiency of TCRs in NOD mice we started with a single cell analysis to compare to a previously analyzed similar model of TCRmini transgenic mice on “healthy” C57BL/6 background (B6mini) [36]. We compared the similarity between TCR sequences from single cell sorted TN (CD4+Foxp3−CD45RB+CD62L+) and Treg (CD4+Foxp3+) cells from thymii and peripheral lymph nodes of NODmini mice. As expected, based on the Morisita-Horn index, the highest similarity was observed between thymic and peripheral subsets of TN or Treg cells, whereas comparison between populations of TN and Treg cells showed mostly non-overlapping repertoires with values similar to those observed on B6 background (Fig. 6A and [36]). Previously we’ve shown that based on abundance coverage estimator (ACE), estimated richness (total unique CDR3α clonotypes in the population) of Treg cells in B6mini mice significantly exceeded estimated richness of TN cells [36]. Although ACE underestimates true richness at low sample size, it accounts for “unseen sequences” based on low abundance data and is suitable for comparative analyses. We combined thymic and peripheral sequences for each population and calculated the ACE index, based on 578 DNA sequences per subset. The ACE values for TN and Treg cells were respectively 1187 and 994 for NODmini mice, and 1184 and 1815 for B6mini mice. Interestingly, estimated ACE value for TCRs on TN cells from NODmini mice was comparable to the ACE value for TCRs on TN cells from B6mini mice. However when we compared the ratio of ACE values for Treg cells between NODmini and B6mini mice the number of possible unique TCRs on NOD background was reduced by almost 50% (Fig. 6B).
Previously it has been reported that based on analysis of two selected VJ (TCRα) or one VDJ (TVRβ) rearrangements in wild type mice, TCR repertoire of Treg cells in NOD mice was less diverse as compared to conventional T cells in the thymus, but also less diverse in the thymus of B6 mice [9]. These differences were observed based on calculation of Shannon entropy and normalization to the logarithm of unique sequences [9]. Such transformation is a measure of distribution of frequency of individual species and is a good measure of relative evenness of assemblage [51], [52]. Together with richness, evenness is a descriptive measure of diversity not the diversity per se [51]. Therefore, as explained by Jost, to put the estimates in perspective, we converted Shannon entropy (diversity index) to “true diversity” by calculating “numbers equivalent” also called “effective number of species” (ENS), to preserve linear scale of comparison [51], [53]. The ENS measure represents diversity of a particular sample, and the numeric value represents the theoretical number of equally common unique sequences in the assemblage. Comparison of “true diversity” between B6mini and NODmini mice showed almost reversal of ratios of diversities between TCRs on TN and Treg cells, with the differences more profound in the thymus than in the periphery (Fig. 6C). These differences in NODmini mice were confirmed by high throughput sequencing, and were consistent regardless of total numbers of sequences analyzed (Fig. 6C, D). Lower diversity of Treg TCR repertoire was visualized empirically by plotting accumulation curves of observed sequences from peripheral TN and Treg cells (Fig. 6E). These curves show that accumulation of unique CDR3 regions from the first 120 thousands of sequences for each population gives twice as many unique DNA clonotypes in TN (9757) as compared to Treg cells (4968). This ratio is reversed in comparison to accumulation curves observed in B6mini mice [36]. Collectively our data show that although TCR diversity on Treg cells in NODmini mice is reduced, conventional T cells retain diverse TCR repertoire at least at the levels found on B6 background.
Discussion
In this study we investigated the impact of the reduction of TCR diversity on the development of two autoimmune diseases in NOD mice; T1D and SS. Previously it has been shown that T1D can develop despite use of transgenic TCRβ chains or reduction of precursor frequency of potentially diabetogenic T cell clones. In our model overall diversity of TCRs was reduced by allelic exclusion caused by use of transgenic TCRβ chain that was not only pathogenically irrelevant, but also was originally selected in B6 mice on I-Ab molecule. Despite normal distribution of Vα families in NODβTg mice, neither insulitis nor diabetes developed. Conversely, these mice developed infiltrates in salivary and lacrimal glands, leading to autoantibody production and exocrine gland dysfunction. Further reduction of TCR diversity by generation of transgenic mice with TCRmini repertoire, where one Vα segment is allowed to rearrange to only two Jα segments, did not prevent development of SS. Our results indicate that the difference between T1D and SS regarding the dependence on MHC polymorphism is directly correlated to the magnitude of possible TCR/peptide/MHCII interactions participating in the autoimmune phase of the disease.
We show that the lack of development of diabetes or even insulitis in our NODβTg or NODmini transgenic mice is due to lack of specificity to the key immunodominant insulin B:9–23 peptide, which is known to be instrumental for the onset of the T1D in NOD mice. The use of transgenic TCRVβ14 chain in our mice did not dramatically influence the ability of its binding to different TCRα chains, as T cells from NODβTg mice use all Vα families with frequencies found in NOD mice (Fig. 1). This includes efficient amplification of the Vα13 family which contains TRAV5D-4 chain (Vα13s1) that was shown to be sufficient to elicit anti-insulin autoimmunity without bias toward particular Vβ family of TCRβ chain partners [28], [54]. Moreover, previous studies show that T cells using Vβ14 family were found on T cells specific to insulin antigen, T cells expanding in pancreatic lymph nodes or in T cells infiltrating pancreatic islets, showing that the Vβ14 family is not negatively influencing the development of diabetogenic TCRs [55]–[58]. One cannot exclude the possibility that this particular transgenic TCRVβ14 chain may be unable to pair with appropriate TCRα chain, preventing the ability of the expressed αβTCR to recognize the B:9–23 peptide. This selective requirement for a TCRβ chain would reinforce our observation that development of SS is less dependent than development of T1D on overall TCR diversity and a particular peptide/MHC combination.
Development of T1D relies on different insulin B:9–23 register recognition, allowing escape of specific T cells due to register shifting [11]–[13]. The lack of peripheral recognition of insulin B:9–23 in our transgenic mice can also be due to the impact of the limited TCR repertoire. Reduction of overall TCR diversity can influence (reduce) the precursor frequency of DP thymocytes bearing potentially autoreactive TCRs, resulting in more efficient negative selection in the thymus of NOD mice. It has been shown that early expression of transgenic αβTCR, due to ERK1/2 defect on NOD background results in greater commitment of the DN thymocytes to αβ lineage “overcrowding” DP compartment [8]. Our TCRαmini transgene has natural timing of expression, similar to B6mini and polyclonal NOD mice, where pre-TCR signaling is not perturbed by early expression of the transgene [36]. As suggested by Mingueneau et. al., in the polyclonal repertoire on the NOD background, the ERK1/2 defect increases the affinity threshold of positive selection, shifting the selection window of thymocytes toward self-reactivity, however not impacting the efficiency of negative selection. This results in higher overall self-reactivity of peripheral effector T cells and possibly explains lower diversity of thymic Treg cells on NOD background [8], [9]. Considering partial overlap of specificities between Treg and autoreactive T cells, one could suggest similar effect of lower diversity on autoreactive population. However weak and unstable peptide-binding property of I-Ag7 molecule does not favor the elimination or inactivation of autoreactive T cells [59]. This instability may have additional influence on “a leak” of autoreactive T cells, but also on inefficient generation of Treg population, which may require longer or stronger interactions with self MHC/peptide complexes [60], [61]. Therefore the shift in selection window will not impact autoreactive T cells as much as it will impact Treg cells, after all, Treg development relies on recognition of self-peptide/MHCII complexes in the thymus, whereas thymic escape of autoreactive T cells relies on avoidance of such complexes during negative selection. It is possible that in our model, we reached the threshold of diversity required to generate autoreactive TCR repertoire without “holes” in specificities. Therefore despite reduced TCR diversity of Treg cells mice do not develop diabetes and we were unable to detect insulin B:9–23 specific T cells in the periphery. Similarly, the comparison of TCRmini repertoires between B6 and NOD backgrounds shows minimal impact of the NOD genotype on TCR diversity of conventional CD4+ T cells however it substantially reduces the TCR diversity on Treg cells in NOD mice.
Development of SS in NODmini mice is especially interesting, since CD4+ T cells are instrumental in immunopathogenesis and their recognition of self antigens is essential for the onset and progression of the disease [34], [62]. It shows that the TCRmini repertoire is diverse enough not only to drive glandular infiltration and activation of the CD4+ T cells but also the repertoire is still diverse enough to support the full development of the disease with production of Th2-dependent IgG1 pathogenic autoantibodies (Fig. 5C) [50]. Moreover, we noticed differences in timing of infiltrates, levels of autoantibodies and total IgG1 production between transgenic mice and parental NOD mice, which indicates different frequencies of certain TCR specificities between mice. In congenic strains of NOD mice models of SS (NOD.B10-H2b, NOD.H2p, NOD.H2q, NOD.H2h4) replacement of I-Ag7 with other MHC molecules does not prevent salivary and lacrimal gland infiltration and decreased saliva and tear production [16], [48], [63]. Interestingly, in NOD.H2h4, contrary to the parental NOD strain, there is a high frequency of ANA with a high proportion of SSA/Ro and SSB/La observed [63]. Also, NOD.H2q mice exhibit increased production of lupus-like types of autoantibodies and develop nephritis, as compared to NOD and NOD.H2p mice [16]. This weak dependence of SS on a particular MHC haplotype in NOD mice correlates with our data that show development of SS despite limited TCR diversity. In human studies it was suggested that production profiles of certain autoantibodies were associated with HLA-DR haplotypes rather than with clinical manifestations [64], however studies of familial inheritance in patients with SS showed a linkage between particular HLA and disease susceptibility [65], [66]. The most recent comprehensive analysis by Sjögren’s Genetics Network showed that HLA has the strongest linkage to the SS, although it is not on the level of T1D [17]. Certain HLA haplotypes will influence binding diversity of self or environmental peptides and the nature of antigen presentation to T cells during thymic development or during immune responses in the periphery. Our results from the mouse model emphasize that SS may be less affected by requirement of a unique key antigen/MHCII combination but rather may be more influenced by a wider range of overall TCR/peptide/MHC interactions involved in the onset/progression of the disease. It can be due to a combination of cross-reactivity of the TCR repertoire on SS-specific T cells, wider range of antigens presented by MHCII molecules, higher peripheral self-reactivity of effector T cells, increased tissue expression of MHCII complexes on salivary epithelial cells and de novo expression or post-translational modification of self-antigens [67]–[69].
Supporting Information
Acknowledgments
Cell sorting was performed by Jeanene Pihkala in the GRU FACS Core, the sequencing was performed by John Nechtman in the GRU Genomic Core, and transgenic mice were generated by Gabriela Pacholczyk in the GRU Transgenic Core.
Data Availability
The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting Information file.
Funding Statement
This research was supported by grants from National Institute of Allergy and Infectious Diseases of the National Institutes of Health (R01AI081798) and Juvenile Diabetes Research Foundation (RP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1. Chaparro RJ, Dilorenzo TP (2010) An update on the use of NOD mice to study autoimmune (Type 1) diabetes. Expert Rev Clin Immunol 6: 939–955. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Lavoie TN, Lee BH, Nguyen CQ (2011) Current concepts: mouse models of Sjogren’s syndrome. J Biomed Biotechnol 2011: 549107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Anderson MS, Bluestone JA (2005) The NOD Mouse: A Model of Immune Dysregulation. Annu Rev Immunol 23: 447–485. [DOI] [PubMed] [Google Scholar]
- 4. Mathis D, Vence L, Benoist C (2001) beta-Cell death during progression to diabetes. Nature 414: 792–798. [DOI] [PubMed] [Google Scholar]
- 5. Nguyen CQ, Peck AB (2009) Unraveling the pathophysiology of Sjogren syndrome-associated dry eye disease. Ocul Surf 7: 11–27. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Fox RI (2005) Sjogren’s syndrome. Lancet 366: 321–331. [DOI] [PubMed] [Google Scholar]
- 7. Kishimoto H, Sprent J (2001) A defect in central tolerance in NOD mice. Nat Immunol 2: 1025–1031. [DOI] [PubMed] [Google Scholar]
- 8. Mingueneau M, Jiang W, Feuerer M, Mathis D, Benoist C (2012) Thymic negative selection is functional in NOD mice. J Exp Med 209: 623–637. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Ferreira C, Singh Y, Furmanski AL, Wong FS, Garden OA, et al. (2009) Non-obese diabetic mice select a low-diversity repertoire of natural regulatory T cells. Proc Natl Acad Sci U S A 106: 8320–8325. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. D’Alise AM, Auyeung V, Feuerer M, Nishio J, Fontenot J, et al. (2008) The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proceedings of the National Academy of Sciences 105: 19857–19862. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Stadinski BD, Zhang L, Crawford F, Marrack P, Eisenbarth GS, et al. (2010) Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register. Proceedings of the National Academy of Sciences 107: 10978–10983. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Mohan JF, Petzold SJ, Unanue ER (2011) Register shifting of an insulin peptide–MHC complex allows diabetogenic T cells to escape thymic deletion. J Exp Med 208: 2375–2383. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Marrack P, Kappler JW (2012) Do MHCII-Presented Neoantigens Drive Type 1 Diabetes and Other Autoimmune Diseases? Cold Spring Harbor Perspectives in Medicine 2. [DOI] [PMC free article] [PubMed]
- 14. Wicker LS, Appel MC, Dotta F, Pressey A, Miller BJ, et al. (1992) Autoimmune syndromes in major histocompatibility complex (MHC) congenic strains of nonobese diabetic (NOD) mice. The NOD MHC is dominant for insulitis and cyclophosphamide-induced diabetes. J Exp Med 176: 67–77. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Li X, Golden J, Faustman DL (1993) Faulty major histocompatibility complex class II I-E expression is associated with autoimmunity in diverse strains of mice. Autoantibodies, insulitis, and sialadenitis. Diabetes 42: 1166–1172. [DOI] [PubMed] [Google Scholar]
- 16. Lindqvist AKB, Nakken B, Sundler M, Kjellen P, Jonsson R, et al. (2005) Influence on Spontaneous Tissue Inflammation by the Major Histocompatibility Complex Region in the Nonobese Diabetic Mouse. Scand J Immunol 61: 119–127. [DOI] [PubMed] [Google Scholar]
- 17. Lessard CJ, Li H, Adrianto I, Ice JA, Rasmussen A, et al. (2013) Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren’s syndrome. Nat Genet 45: 1284–1292. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, et al. (2005) Prime role for an insulin epitope in the development of type[thinsp]1 diabetes in NOD mice. Nature 435: 220–223. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Arakaki R, Ishimaru N, Saito I, Kobayashi M, Yasui N, et al. (2003) Development of autoimmune exocrinopathy resembling Sjögren’s syndrome in adoptively transferred mice with autoreactive CD4+ T cells. Arthritis Rheum 48: 3603–3609. [DOI] [PubMed] [Google Scholar]
- 20. Takada K, Takiguchi M, Konno A, Inaba M (2005) Autoimmunity against a tissue kallikrein in IQI/Jic Mice: a model for Sjogren’s syndrome. J Biol Chem 280: 3982–3988. [DOI] [PubMed] [Google Scholar]
- 21. Winer S, Astsaturov I, Cheung R, Tsui H, Song A, et al. (2002) Primary Sjögren’s syndrome and deficiency of ICA69. Lancet 360: 1063–1069. [DOI] [PubMed] [Google Scholar]
- 22. Haneji N, Nakamura T, Takio K, Yanagi K, Higashiyama H, et al. (1997) Identification of alpha-fodrin as a candidate autoantigen in primary Sjogren’s syndrome. Science 276: 604–607. [DOI] [PubMed] [Google Scholar]
- 23. Naito Y, Matsumoto I, Wakamatsu E, Goto D, Ito S, et al. (2006) Altered peptide ligands regulate muscarinic acetylcholine receptor reactive T cells of patients with Sjogren’s syndrome. Ann Rheum Dis 65: 269–271. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Matsumoto I, Maeda T, Takemoto Y, Hashimoto Y, Kimura F, et al. (1999) Alpha-amylase functions as a salivary gland-specific self T cell epitope in patients with Sjogren’s syndrome. Int J Mol Med 3: 485–490. [DOI] [PubMed] [Google Scholar]
- 25. Iizuka M, Wakamatsu E, Tsuboi H, Nakamura Y, Hayashi T, et al. (2010) Pathogenic role of immune response to M3 muscarinic acetylcholine receptor in Sjogren’s syndrome-like sialoadenitis. J Autoimmun 35: 383–389. [DOI] [PubMed] [Google Scholar]
- 26. Lipes MA, Rosenzweig A, Tan KN, Tanigawa G, Ladd D, et al. (1993) Progression to diabetes in nonobese diabetic (NOD) mice with transgenic T cell receptors. Science 259: 1165–1169. [DOI] [PubMed] [Google Scholar]
- 27. Serreze DV, Johnson EA, Chapman HD, Graser RT, Marron MP, et al. (2001) Autoreactive diabetogenic T-cells in NOD mice can efficiently expand from a greatly reduced precursor pool. Diabetes 50: 1992–2000. [DOI] [PubMed] [Google Scholar]
- 28. Zhang L, Jasinski JM, Kobayashi M, Davenport B, Johnson K, et al. (2009) Analysis of T cell receptor beta chains that combine with dominant conserved TRAV5D-4*04 anti-insulin B: 9–23 alpha chains. J Autoimmun 33: 42–49. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Dwyer E, Itescu S, Winchester R (1993) Characterization of the primary structure of T cell receptor beta chains in cells infiltrating the salivary gland in the sicca syndrome of HIV-1 infection. Evidence of antigen-driven clonal selection suggested by restricted combinations of V beta J beta gene segment usage and shared somatically encoded amino acid residues. J Clin Invest 92: 495–502. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Matsumoto I, Okada S, Kuroda K, Iwamoto I, Saito Y, et al. (1999) Single cell analysis of T cells infiltrating labial salivary glands from patients with Sjogren’s syndrome. IntJ Mol Med 4: 519–527. [DOI] [PubMed] [Google Scholar]
- 31. Pivetta B, De Vita S, Ferraccioli G, De RV, Gloghini A, et al. (1999) T cell receptor repertoire in B cell lymphoproliferative lesions in primary Sjogren’s syndrome. J Rheumatol 26: 1101–1109. [PubMed] [Google Scholar]
- 32. Sumida T, Yonaha F, Maeda T, Tanabe E, Koike T, et al. (1992) T cell receptor repertoire of infiltrating T cells in lips of Sjogren’s syndrome patients. J Clin Invest 89: 681–685. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Yonaha F, Sumida T, Maeda T, Tomioka H, Koike T, et al. (1992) Restricted junctional usage of T cell receptor V beta 2 and V beta 13 genes, which are overrepresented on infiltrating T cells in the lips of patients with Sjogren’s syndrome. Arthritis Rheum 35: 1362–1367. [DOI] [PubMed] [Google Scholar]
- 34. Singh N, Cohen PL (2012) The T cell in Sjogren’s syndrome: Force majeure, not spectateur. J Autoimmun 39: 229–233. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Sumida T, Tsuboi H, Iizuka M, Hirota T, Asashima H, et al. (2014) The role of M3 muscarinic acetylcholine receptor reactive T cells in Sjögren’s syndrome: A critical review. J Autoimmun. [DOI] [PubMed] [Google Scholar]
- 36. Pacholczyk R, Ignatowicz H, Kraj P, Ignatowicz L (2006) Origin and T cell receptor diversity of Foxp3+CD4+CD25+ T cells. Immunity 25: 249–259. [DOI] [PubMed] [Google Scholar]
- 37. Cha S, Nagashima H, Brown VB, Peck AB, Humphreys-Beher MG (2002) Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjogren’s syndrome) on a healthy murine background. Arthritis Rheum 46: 1390–1398. [DOI] [PubMed] [Google Scholar]
- 38. Pacholczyk R, Kern J, Singh N, Iwashima M, Kraj P, et al. (2007) Nonself-antigens are the cognate specificities of Foxp3+ regulatory T cells. Immunity 27: 493–504. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Kisielow J, Tortola L, Weber J, Karjalainen K, Kopf M (2011) Evidence for the divergence of innate and adaptive T-cell precursors before commitment to the alphabeta and gammadelta lineages. Blood 118: 6591–6600. [DOI] [PubMed] [Google Scholar]
- 40. Kraj P, Pacholczyk R, Ignatowicz L (2001) Alpha beta TCRs differ in the degree of their specificity for the positively selecting MHC/peptide ligand. J Immunol 166: 2251–2259. [DOI] [PubMed] [Google Scholar]
- 41. Pacholczyk R, Kraj P, Ignatowicz L (2002) Peptide specificity of thymic selection of CD4+CD25+ T cells. J Immunol 168: 613–620. [DOI] [PubMed] [Google Scholar]
- 42. Lutsiak MEC, Semnani RT, De Pascalis R, Kashmiri SVS, Schlom J, et al. (2005) Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105: 2862–2868. [DOI] [PubMed] [Google Scholar]
- 43. Harada M, Makino S (1984) Promotion of spontaneous diabetes in non-obese diabetes-prone mice by cyclophosphamide. Diabetologia 27: 604–606. [DOI] [PubMed] [Google Scholar]
- 44. Michels AW, Ostrov DA, Zhang L, Nakayama M, Fuse M, et al. (2011) Structure-Based Selection of Small Molecules To Alter Allele-Specific MHC Class II Antigen Presentation. The Journal of Immunology 187: 5921–5930. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Cha S, Peck AB, Humphreys-Beher MG (2002) Progress in understanding autoimmune exocrinopathy using the non-obese diabetic mouse: an update. Crit RevOral BiolMed 13: 5–16. [DOI] [PubMed] [Google Scholar]
- 46. Atkinson JC, Travis WD, Slocum L, Ebbs WL, Fox PC (1992) Serum anti-SS-B/La and IgA rheumatoid factor are markers of salivary gland disease activity in primary Sjogren’s syndrome. Arthritis Rheum 35: 1368–1372. [DOI] [PubMed] [Google Scholar]
- 47. Skarstein K, Wahren M, Zaura E, Hattori M, Jonsson R (1995) Characterization of T cell receptor repertoire and anti-Ro/SSA autoantibodies in relation to sialadenitis of NOD mice. Autoimmunity 22: 9–16. [DOI] [PubMed] [Google Scholar]
- 48. Robinson CP, Yamachika S, Bounous DI, Brayer J, Jonsson R, et al. (1998) A novel NOD-derived murine model of primary Sjogren’s syndrome. Arthritis Rheum 41: 150–156. [DOI] [PubMed] [Google Scholar]
- 49. Brayer JB, Cha S, Nagashima H, Yasunari U, Lindberg A, et al. (2001) IL-4-dependent effector phase in autoimmune exocrinopathy as defined by the NOD.IL-4-gene knockout mouse model of Sjogren’s syndrome. ScandJImmunol 54: 133–140. [DOI] [PubMed] [Google Scholar]
- 50. Gao J, Killedar S, Cornelius JG, Nguyen C, Cha S, et al. (2006) Sjogren’s syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotype-specific autoimmune disease. J Autoimmun 26: 90–103. [DOI] [PubMed] [Google Scholar]
- 51. Jost L (2010) The Relation between Evenness and Diversity. Diversity 2: 207–232. [Google Scholar]
- 52. Pielou EC (1966) The measurement of diversity in different types of biological collections. J Theor Biol 13: 131–144. [Google Scholar]
- 53. Adelman MA (1969) Comment on the H Concentration Measure as a Numbers-Equivalent. The Review of Economics and Statistics 51: 99–101. [Google Scholar]
- 54. Nakayama M, Castoe T, Sosinowski T, He X, Johnson K, et al. (2012) Germline TRAV5D-4 T-Cell Receptor Sequence Targets a Primary Insulin Peptide of NOD Mice. Diabetes 61: 857–865. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55. Simone E, Daniel D, Schloot N, Gottlieb P, Babu S, et al. (1997) T cell receptor restriction of diabetogenic autoimmune NOD T cells. Proceedings of the National Academy of Sciences 94: 2518–2521. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56. Baker FJ, Lee M, Chien Y-h, Davis MM (2002) Restricted islet-cell reactive T cell repertoire of early pancreatic islet infiltrates in NOD mice. Proceedings of the National Academy of Sciences 99: 9374–9379. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57. Marrero I, Hamm DE, Davies JD (2013) High-Throughput Sequencing of Islet-Infiltrating Memory CD4+ T Cells Reveals a Similar Pattern of TCR Vβ Usage in Prediabetic and Diabetic NOD Mice. PLoS ONE 8: e76546. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Petrovc Berglund J, Mariotti-Ferrandiz E, Rosmaraki E, Hall H, Cazenave P-A, et al. (2008) TCR repertoire dynamics in the pancreatic lymph nodes of non-obese diabetic (NOD) mice at the time of disease initiation. Mol Immunol 45: 3059–3064. [DOI] [PubMed] [Google Scholar]
- 59. Carrasco-Marin E, Shimizu J, Kanagawa O, Unanue ER (1996) The class II MHC I-Ag7 molecules from non-obese diabetic mice are poor peptide binders. J Immunol 156: 450–458. [PubMed] [Google Scholar]
- 60. Aschenbrenner K, D’Cruz LM, Vollmann EH, Hinterberger M, Emmerich J, et al. (2007) Selection of Foxp3+ regulatory T cells specific for self antigen expressed and presented by Aire+ medullary thymic epithelial cells. Nat Immunol 8: 351–358. [DOI] [PubMed] [Google Scholar]
- 61. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, et al. (2005) Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22: 329–341. [DOI] [PubMed] [Google Scholar]
- 62. Sumida T, Tsuboi H, Iizuka M, Nakamura Y, Matsumoto I (2010) Functional role of M3 muscarinic acetylcholine receptor (M3R) reactive T cells and anti-M3R autoantibodies in patients with Sjögren’s syndrome. Autoimmunity Reviews 9: 615–617. [DOI] [PubMed] [Google Scholar]
- 63. Burek CL, Talor MV, Sharma RB, Rose NR (2007) The NOD.H2h4 mouse shows characteristics of human Sjogren’s Syndrome. J Immunol 178: S232–S223d. [Google Scholar]
- 64. Gottenberg JE, Busson M, Loiseau P, Cohen-Solal J, Lepage V, et al. (2003) In primary Sjogren’s syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum 48: 2240–2245. [DOI] [PubMed] [Google Scholar]
- 65. Fox RI, Kang HI (1992) Pathogenesis of Sjogren’s syndrome. RheumDisClinNorth Am 18: 517–538. [PubMed] [Google Scholar]
- 66. Manoussakis MN, Georgopoulou C, Zintzaras E, Spyropoulou M, Stavropoulou A, et al. (2004) Sjogren’s syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjogren’s syndrome. Arthritis Rheum 50: 882–891. [DOI] [PubMed] [Google Scholar]
- 67. Anderton SM (2004) Post-translational modifications of self antigens: implications for autoimmunity. Curr Opin Immunol 16: 753–758. [DOI] [PubMed] [Google Scholar]
- 68. Engelhard VH, Altrich-Vanlith M, Ostankovitch M, Zarling AL (2006) Post-translational modifications of naturally processed MHC-binding epitopes. Curr Opin Immunol 18: 92–97. [DOI] [PubMed] [Google Scholar]
- 69. Moutsopoulos HM, Hooks JJ, Chan CC, Dalavanga YA, Skopouli FN, et al. (1986) HLA-DR expression by labial minor salivary gland tissues in Sjogren’s syndrome. Ann Rheum Dis 45: 677–683. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting Information file.